TrialBlood advances2024

Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma.

Shlomit Kfir-Erenfeld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.